Home › NCT06944847
Vaping and Smoking Project in People With Schizophrenia
A Laboratory Study of Behavior and Performance Among People Who Vape Nicotine and/or Smoke Cigarettes - Schizophrenia Supplement
Who can join
Ages 21 to 50 · All sexes
Full eligibility criteria
Inclusion Criteria: * 6+ months of daily/near-daily nicotine vaping or cigarette smoking * 200+ ng/mL cotinine on a commercially-available quick screen * stable antipsychotic medication dose (no changes in past 6 months). Current Exclusion Criteria: * intention to quit daily/near-daily vaping/smoking in the next month * current (2+ days out of the past 7) use of pipe tobacco, hookah/shisha, smokeless tobacco, dissolvable tobacco, nicotine pouches. For vaping group only, current (2+ days out of past 7) use of cigars, cigarillos, or filtered cigars that are filled with tobacco or a mix of tobacco and marijuana * current use of any smoking cessation medication * current severe substance dependence other than tobacco/nicotine (including cannabis; NIDA Modified ASSIST of 27+) * current (past 2 weeks) suicidal ideation with intent and/or plan * pregnancy (intake urine screen) * florid psychosis or severe cognitive symptoms (score of ≥5 on PANSS items delusions (P1), hallucinatory behavior (P3), or unusual thought content (G9), conceptual disorganization (P2), abstract thinking (N5), or poor attention (G11) or a score ≥6 on grandiosity (P5) or suspiciousness (P6)
About the study
The proposed research will characterize withdrawal among people with schizophrenia who vape daily compared to people with schizophrenia who smoke combustible cigarettes daily, filling critical gaps in the understanding of electronic nicotine delivery systems (ENDS) dependence and contributing to the development of vaping cessation interventions amongst people with schizophrenia, the leading preventable cause of death in the US.
What is being tested
- Acute (24-hour) abstinence (behavioral)
- Ad libitum smoking/vaping (behavioral)
Sponsor: State University of New York at Buffalo · Participants: 64 · Started: Feb 15, 2025
Contact the study team
- Larry Hawk, PhD · Phone: 716-645-0192
Official record on ClinicalTrials.gov — NCT06944847
Locations in the U.S.
| New York | University at Buffalo, Buffalo |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.